Suppression of growth, migration and invasion of highly-metastatic human breast cancer cells by berbamine and its molecular mechanisms of action

Molecular Cancer

Volumn 8, Issue , 2009, Pages 81-

  Wang, Shan ^a   Liu, Qian ^a   Zhang, Ying ^b   Liu, Ke ^a   Yu, Pengfei ^a   Liu, Kun ^a   Luan, Jinling ^a   Duan, Huiying ^a   Lu, Zhaoqiao ^a   Wang, Fengfei ^c   Wu, Erxi ^c   Yagasaki, Kazumi ^d   Zhang, Guoying ^a  

^a YANTAI UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c NORTH DAKOTA STATE UNIVERSITY   (United States)

^d TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BERBAMINE; CARMOFUR; CELECOXIB; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOPONTIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SYNAPTOTAGMIN I; TRICHOSTATIN A; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL CULTURE; CANCER INHIBITION; CANCER INVASION; CELL CYCLE; CELL MIGRATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZYLISOQUINOLINES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME ACTIVATION; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NF-KAPPA B; OSTEOPONTIN; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 70449669190     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-81     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
2. Park S, Bae J, Nam BH, Yoo KY. Aetiology of cancer in Asia. Asian Pac J Cancer Prev 2008, 9(3):371-80.
3. Ziegler RG, Anderson WF, Gail MH. Increasing breast cancer incidence in China: the numbers add up. J Natl Cancer Inst 2008, 100(19):1339-41. 10.1093/jnci/djn330, 18812546.
4. Xu R, Dong Q, Yu Y, Zhao X, Gan X, Wu D, Lu Q, Xu X, Yu XF. Berbamine: a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity. Leuk Res 2006, 30(1):17-23. 10.1016/j.leukres.2005.05.023, 16023722.
5. Dong Y, Yang MM, Kwan CY. In vitro inhibition of proliferation of HL-60 cells by tetrandrine and coriolus versicolor peptide derived from Chinese medicinal herbs. Life Sci 1997, 60(8):PL135-40. 10.1016/S0024-3205(96)00695-9, 9042394.
6. Sun JR, Zhang XH, He ZW, Gu Y, Yu YZ, Fang YM, Lu QH, Dong QH, Xu RZ. The mechanism of apoptosis of chronic myeloid leukemia cells induced by the novel p210 bcr/abl inhibitor berbamine. Zhonghua Yi Xue Za Zhi 2006, 86(32):2246-51.
7. Zhao XY, He ZW, Wu D, Xu RZ. Berbamine selectively induces apoptosis of human acute promyelocytic leukemia cells via survivin-mediated pathway. Chin Med J (Engl) 2007, 120(9):802-6.
8. Wang GY, Zhang JW, Lu QH, Xu RZ, Dong QH. Berbamine induces apoptosis in human hepatoma cell line SMMC7721 by loss in mitochondrial transmembrane potential and caspase activation. J Zhejiang Univ Sci B 2007, 8(4):248-55. 10.1631/jzus.2007.B0248, 1838830, 17444599.
9. Rangaswami H, Bulbule A, Kundu GC. Nuclear factor-inducing kinase plays a crucial role in osteopontin-induced MAPK/IkappaBalpha kinase-dependent nuclear factor kappaB-mediated promatrix metalloproteinase-9 activation. J Biol Chem 2004, 279(37):38921-35. 10.1074/jbc.M404674200, 15247285.
10. Folkman J. Angiogenic zip code. Nat Biotechnol 1999, 17(8):749. 10.1038/11676, 10429233.
11. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, Kantor C, Gahmberg CG, Salo T, Konttinen YT, Sorsa T, Ruoslahti E, Pasqualini R. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 1999, 17(8):768-74. 10.1038/11703, 10429241.
12. Philip S, Bulbule A, Kundu GC. Osteopontin stimulates tumor growth and activation of promatrix metalloproteinase-2 through nuclear factor-kappa B-mediated induction of membrane type 1 matrix metalloproteinase in murine melanoma cells. J Biol Chem 2001, 276(48):44926-35. 10.1074/jbc.M103334200, 11564733.
13. Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H. Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 2002, 73(3):237-43. 10.1023/A:1015872531675, 12160329.
14. Das R, Mahabeleshwar GH, Kundu GC. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 2003, 278(31):28593-606. 10.1074/jbc.M303445200, 12771144.
15. Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci USA 2003, 100(16):9482-7. 10.1073/pnas.1633689100, 170944, 12874388.
16. Samant RS, Clark DW, Fillmore RA, Cicek M, Metge BJ, Chandramouli KH, Chambers AF, Casey G, Welch DR, Shevde LA. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 2007, 6:6. 10.1186/1476-4598-6-6, 1796551, 17227585.
17. Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, Cheng N. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther 2007, 6(4):561-70.
18. Eder JP, Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009, 15(7):2207-14. 10.1158/1078-0432.CCR-08-1306, 19318488.
19. Toker A. Protein kinases as mediators of phosphoinositide 3-kinase signaling. Mol Pharmacol 2000, 57(4):652-8.
20. Koyasu S. The role of PI3K in immune cells. Nat Immunol 2003, 4(4):313-9. 10.1038/ni0403-313, 12660731.
21. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96(6):857-68. 10.1016/S0092-8674(00)80595-4, 10102273.
22. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998, 10(2):262-7. 10.1016/S0955-0674(98)80149-X, 9561851.
23. Sizemore N, Leung S, Stark GR. Activation of phosphatidylinositol 3-kinase in response to interleukin-1 leads to phosphorylation and activation of the NF-kappaB p65/RelA subunit. Mol Cell Biol 1999, 19(7):4798-805. 84278, 10373529.
24. Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM, Donner DB. NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 1999, 401(6748):82-5. 10.1038/43466, 10485710.
25. Wang CY, Mayo MW, Baldwin AS. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science 1996, 274(5288):784-7. 10.1126/science.274.5288.784, 8864119.
26. Tang Y, Nakada MT, Rafferty P, Laraio J, McCabe FL, Millar H, Cunningham M, Snyder LA, Bugelski P, Yan L. Regulation of vascular endothelial growth factor expression by EMMPRIN via the PI3K-Akt signaling pathway. Mol Cancer Res 2006, 4(6):371-7. 10.1158/1541-7786.MCR-06-0042, 16778084.
27. Lee TH, Seng S, Sekine M, Hinton C, Fu Y, Avraham HK, Avraham S. Vascular endothelial growth factor mediates intracrine survival in human breast carcinoma cells through internally expressed VEGFR1/FLT1. PLoS Med 2007, 4(6):e186. 10.1371/journal.pmed.0040186, 1885450,1885450, 17550303.
28. Li B, Gao Y, Li H. Determination of berbamine in rat plasma by reversed phase high performance liquid chromatography. Journal of Harbin Medical University (Chinese) 1995, 29(3):201-2.
29. Yang F, Jin SY, Li YX, Li WH, Yi MG. Absorption, distribution and elimination of tritium labeled berbamine. Journal of Harbin Medical University 1988, 22(2):103-4.
30. Viatour P, Bentires-Alj M, Chariot A, Deregowski V, de Leval L, Merville MP, Bours V. NF- kappa B2/p100 induces Bcl-2 expression. Leukemia 2003, 17(7):1349-56. 10.1038/sj.leu.2402982, 12835724.
31. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292(5517):727-30. 10.1126/science.1059108, 11326099.
32. Marsden VS, O'Connor L, O'Reilly LA, Silke J, Metcalf D, Ekert PG, Huang DC, Cecconi F, Kuida K, Tomaselli KJ, Roy S, Nicholson DW, Vaux DL, Bouillet P, Adams JM, Strasser A. Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature 2002, 419(6907):634-7. 10.1038/nature01101, 12374983.
33. Mayo LD, Donner DB. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci 2002, 27(9):462-7. 10.1016/S0968-0004(02)02166-7, 12217521.
34. Nicholson KM, Anderson NG. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal 2002, 14(5):381-95. 10.1016/S0898-6568(01)00271-6, 11882383.
35. Patel JB, Mehta J, Belosay A, Sabnis G, Khandelwal A, Brodie AM, Soprano DR, Njar VC. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer 2007, 96(8):1204-15. 10.1038/sj.bjc.6603705, 2360155, 17387344.
36. Gupta S, Afaq F, Mukhtar H. Involvement of nuclear factor-kappa B, Bax and Bcl-2 in induction of cell cycle arrest and apoptosis by apigenin in human prostate carcinoma cells. Oncogene 2002, 21(23):3727-38. 10.1038/sj.onc.1205474, 12032841.
37. Emi M, Kim R, Tanabe K, Uchida Y, Toge T. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res 2005, 7(6):R940-52. 10.1186/bcr1323, 1410745, 16280040.
38. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer cell 2004, 6(3):203-8. 10.1016/j.ccr.2004.09.003, 15380510.
39. Knudsen BS, Woude G. Showering c-MET-dependent cancers with drugs. Curr Opin Genet Dev 2008, 18(1):87-96. 10.1016/j.gde.2008.02.001, 18406132.
40. Lowery AJ, Sweeney KJ, Molloy AP, Hennessy E, Curran C, Kerin MJ. The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer. BMC cancer 2008, 8:279. 10.1186/1471-2407-8-279, 2569957, 18826631.
41. Ross DT, Scherf U, Eisen MB, Perou CM, Rees C, Spellman P, Iyer V, Jeffrey SS, Rijn M, Waltham M, Pergamenschikov A, Lee JC, Lashkari D, Shalon D, Myers TG, Weinstein JN, Botstein D, Brown PO. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000, 24(3):227-35. 10.1038/73432, 10700174.
42. Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC. Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 2002, 55(5):294-9. 10.1136/mp.55.5.294, 1187258, 12354931.
43. Sellappan S, Grijalva R, Zhou X, Yang W, Eli MB, Mills GB, Yu D. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. Cancer Res 2004, 64(10):3479-85. 10.1158/0008-5472.CAN-3299-2, 15150101.
44. Hollestelle A, Schutte M. Comment Re: MDA-MB-435 and M14 Cell Lines: Identical but not M14 Melanoma?. Cancer Res 2009,
45. Chambers AF. MDA-MB-435 and M14 cell lines: identical but not M14 melanoma?. Cancer Res 2009, 69(13):5292-3. 10.1158/0008-5472.CAN-09-1528, 19549886.
46. Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature 2009, 458(7239):725-31. 10.1038/nature07782, 19279572, 2692085.
47. Zhang G, Miura Y, Yagasaki K. Induction of apoptosis and cell cycle arrest in cancer cells by in vivo metabolites of teas. Nutr Cancer 2000, 38(2):265-73. 10.1207/S15327914NC382_16, 11525605.
48. Zhang Y, Zhang H, Yu P, Liu Q, Liu K, Duan H, Luan G, Yagasaki K, Zhang G. Effects of matrine against the growth of human lung cancer and hepatoma cells as well as lung cancer cell migration. Cytotechnology 2009,
49. Huang Y, Liu Q, Liu K, Yagasaki K, Zhang G. Suppression of growth of highly-metastatic human breast cancer cells by norcantharidin and its mechanisms of action. Cytotechnology 2009,